| Global statistics on alcohol, tobacco and illicit drug use: 2017 status report |
76 |
| Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis |
62 |
| Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs |
35 |
| Alcohol industry involvement in policymaking: a systematic review |
31 |
| Corrected US opioid-involved drug poisoning deaths and mortality rates, 1999-2015 |
30 |
| A transdiagnostic dimensional approach towards a neuropsychological assessment for addiction: an international Delphi consensus study |
28 |
| Gateway effects and electronic cigarettes |
25 |
| Increasing potency and price of cannabis in Europe, 2006-16 |
25 |
| Gendered violence and overdose prevention sites: a rapid ethnographic study during an overdose epidemic in Vancouver, Canada |
24 |
| A crisis of opioids and the limits of prescription control: United States |
24 |
| 'Are The Times A-Changin'? Trends in adolescent substance use in Europe |
23 |
| A systematic review of the next-day effects of heavy alcohol consumption on cognitive performance |
23 |
| Compliance with ecological momentary assessment protocols in substance users: a meta-analysis |
22 |
| Predictors of smoking cessation during pregnancy: a systematic review and meta-analysis |
22 |
| Rising pregabalin use and misuse in Australia: trends in utilization and intentional poisonings |
22 |
| The prevalence, incidence, and gender and age-specific incidence of problem gambling: results of the Swedish longitudinal gambling study (Swelogs) |
22 |
| Associations between adolescent cannabis use and neuropsychological decline: a longitudinal co-twin control study |
22 |
| Prevalence of fetal alcohol spectrum disorder among special subpopulations: a systematic review and meta-analysis |
20 |
| Modelling the combined impact of interventions in averting deaths during a synthetic-opioid overdose epidemic |
20 |
| Illicit fentanyls in the opioid street market: desired or imposed? |
19 |
| Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder |
18 |
| Medical marijuana laws and adolescent marijuana use in the United States: a systematic review and meta-analysis |
18 |
| Carbonyl emissions from a novel heated tobacco product (IQOS): comparison with an e-cigarette and a tobacco cigarette |
18 |
| Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice? |
17 |
| Extended-release injectable naltrexone for opioid use disorder: a systematic review |
17 |
| Underestimation of alcohol consumption in cohort studies and implications for alcohol's contribution to the global burden of disease |
17 |
| The impact of buprenorphine and methadone on mortality: a primary care cohort study in the United Kingdom |
17 |
| Measuring spatial and temporal trends of nicotine and alcohol consumption in Australia using wastewater-based epidemiology |
16 |
| Moderators of real-world effectiveness of smoking cessation aids: a population study |
15 |
| Trends and age, period and cohort effects for marijuana use prevalence in the 1984-2015 US National Alcohol Surveys |
15 |
| Moral disapproval and perceived addiction to internet pornography: a longitudinal examination |
15 |
| Prevalence of youth gambling and potential influence of substance use and other risk factors throughout 33 European countries: first results from the 2015 ESPAD study |
15 |
| Medical cannabis legalization and opioid prescriptions: evidence on US Medicaid enrollees during 1993-2014 |
15 |
| A meta-analysis of the efficacy of gabapentin for treating alcohol use disorder |
14 |
| Harm perceptions of e-cigarettes and other nicotine products in a UK sample |
14 |
| All drinking is not equal: how a social practice theory lens could enhance public health research on alcohol and other health behaviours |
14 |
| Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate |
14 |
| Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder |
13 |
| High-intensity cannabis use is associated with retention in opioid agonist treatment: a longitudinal analysis |
13 |
| 'Real-world' compensatory behaviour with low nicotine concentration e-liquid: subjective effects and nicotine, acrolein and formaldehyde exposure |
13 |
| Factors associated with the efficacy of smoking cessation treatments and predictors of smoking abstinence in EAGLES |
13 |
| Prevalence of awareness, ever-use and current use of nicotine vaping products (NVPs) among adult current smokers and ex-smokers in 14 countries with differing regulations on sales and marketing of NVPs: cross-sectional findings from the ITC Project |
13 |
| Profiles of recovery from alcohol use disorder at three years following treatment: can the definition of recovery be extended to include high functioning heavy drinkers? |
12 |
| Cannabidiol reverses attentional bias to cigarette cues in a human experimental model of tobacco withdrawal |
12 |
| Methods of the ITC Four Country Smoking and Vaping Survey, wave 1 (2016) |
12 |
| Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study |
12 |
| Price elasticity of illegal versus legal cannabis: a behavioral economic substitutability analysis |
12 |
| Will growth in cryptomarket drug buying increase the harms of illicit drugs? |
12 |
| Understanding and using time series analyses in addiction research |
12 |
| Medical complications associated with substance use disorders in patients with type 2 diabetes and hypertension: electronic health record findings |
12 |
